ZALTRAP Special Drug Use Surveillance (Unresectable advanced and/or recurrent colorectal cancer)
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ZALTRAP
- Sponsors Sanofi K.K.
- 06 Sep 2019 Status changed from recruiting to active, no longer recruiting.
- 15 Jan 2018 Status changed from not yet recruiting to recruiting.
- 03 Nov 2017 New trial record